CMS final rule on Medicare Advantage and Part D drug prices
The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs. The rule finalizes language aimed at increasing transparency for Part D beneficiaries, as well as the option for MA plans to utilize step therapy for Part B drugs.
Related News Articles
Headline
The AHA July 11 released its quarterly Health Care Plan Accountability Update, a roundup of news, letters, statements and other resources covering private…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Healthcare Equality Network July 3 sent a letter to the Centers for Medicare & Medicaid Services, expressing concerns about claims denials by…
Headline
The Department of Health and Human Services’ Office of Inspector General last week announced its intent to investigate Medicare Advantage Organizations’ prior…
Headline
The Medicare Payment Advisory Commission June 13 released its June report to Congress. As urged by the AHA, the commission did not recommend a payment…
Headline
The AHA praised House and Senate leaders in letters June 12 for reintroducing the Improving Seniors’ Timely Access to Care Act, bipartisan legislation that…